The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Idefirix Market In 2026 And How Much Will It Reach By 2030?
The expansion observed during the historical timeframe can be attributed to a scarcity of organs available for kidney transplantation, a widespread presence of donor-specific antibodies, the inherent limitations of conventional desensitization techniques, the initial positive clinical results demonstrated by imlifidase, and an increase in the number of transplant centers.
The projected growth during the forecast period is influenced by an increasing demand for kidney transplants, the lengthening of transplant waiting lists, the broader adoption of precision immunology, advantageous regulatory systems, and the establishment of more specialized transplant clinics. Significant developments anticipated in the forecast timeframe encompass the rising application of desensitization therapies within transplantation, an enhanced focus on highly sensitized patients, the expansion of enzyme-based immunomodulation, an upward trend in kidney transplant volumes, and improved accessibility to advanced transplant care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp
What Major Growth Factors Are Impacting The Idefirix Market?
The future expansion of the idefirix market is anticipated due to the rising occurrence and new cases of kidney diseases. These conditions impair the kidneys’ structure or functionality, impeding their capacity to purify waste and regulate bodily fluid levels. The growing number of kidney disease cases and their increasing frequency stem from factors like an older demographic, escalating rates of diabetes and high blood pressure, individual lifestyle decisions, and inherited genetic susceptibilities. Idefirix, an innovative enzyme therapy that breaks down immunoglobulin G (IgG), aids individuals with kidney disease by allowing highly sensitized patients to receive vital kidney transplants through its effectiveness in lowering donor-specific antibodies that would typically lead to rejection. As an illustration, a June 2023 report from kidney research, a UK-based organization, indicated that the incidence of acute kidney injury is forecast to climb from approximately 615,000 cases in 2022 to 637,000 by 2033. Consequently, the expanding prevalence and incidence of kidney diseases are propelling the expansion of the idefirix market.
What Segment Categories Are Evaluated In The Idefirix Market Study?
The idefirix market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Kidney Transplantation, Desensitization Protocols
3) By End-User: Hospitals, Specialized Clinics, Home Healthcare
4) By Distribution Channel: Direct Sales, Pharmacies
What Trends Are Shaping The Idefirix Market Structure?
A primary trend within the idefirix market involves concentrating on creating cutting-edge solutions, like desensitization treatment, aimed at desensitizing kidney transplant patients who are highly sensitized. This medical procedure, desensitization treatment, functions by eliminating or decreasing detrimental antibodies, thereby allowing transplant patients to accept organs from donors with whom they are otherwise incompatible. An example of this is Hansa Biopharma, a biopharmaceutical firm based in Sweden, announcing in July 2023 that Idefirix (imlifidase) received approval from the Australian Therapeutic Goods Administration (TGA), Australia’s regulatory body, for use as a desensitization treatment for kidney transplant patients with high sensitization. Such approval facilitates these patients in undergoing kidney transplants sourced from both living and deceased donors. The mechanism of this treatment involves diminishing or clearing harmful anti-donor antibodies, which would otherwise impede successful transplantation. This approval, stemming from favorable outcomes observed in Hansa Biopharma’s phase 2 studies, signifies a substantial advancement in broadening kidney transplant possibilities for highly sensitized patients across Australia.
Who Are The Prominent Players Across The Idefirix Market?
Major companies operating in the idefirix market are Hansa Biopharma AB
Access The Complete Idefirix Market Report:
https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report
What Is The Largest Regional Market In The Idefirix Market?
Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model